CARC 55: Procedure/treatment/drug is deemed experimental/investigational by the payer.

CARC 55 appears on the 835 ERA (Electronic Remittance Advice) that the payer returns after claim adjudication. It explains a reduction, denial, or payment adjustment to your billing team. For your practice, the question is workflow: identify the pattern, route the denial to the right resolution path (rebill, appeal, write-off), and recover what's recoverable without burning RVU time on dead-end fights.

What CARC 55 means

The official X12 description is: “Procedure/treatment/drug is deemed experimental/investigational by the payer.”

In plain language: The carrier classified the treatment as experimental. Appealable when FDA-approved, peer-reviewed, or guideline-recommended for your specific indication.

Common scenarios

• Off-label oncology drug use
• Newer biologic
• Genetic testing for treatment selection
• Functional medicine therapies

Practice workflow for CARC X 55

Appeal by citing FDA approval for your indication, peer-reviewed literature supporting the treatment, and specialty-society guidelines. Insurers often misapply 'experimental' to off-label-but-evidence-based treatments. For cancer, NCCN compendium use is particularly strong.

ApprovalHelp auto-drafts the appeal letter against the right federal appeal-rights regulation (ACA §2719, ERISA §503, NSA §2799A, 42 CFR 422 Subpart M, or 42 CFR 438 Subpart F) for the patient's plan type, the payer's own coverage policy, and the relevant clinical guideline. Drafts route to the clinician for signature in under five minutes.

CARC 55 group codes explained

On the 835 ERA, CARC 55 appears alongside a group code that signals who is financially responsible for the adjustment. CO (Contractual Obligation) — Contractual write-off. The provider agreed to the rate. Patient does NOT owe this amount.